全文获取类型
收费全文 | 1483篇 |
免费 | 110篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 83篇 |
妇产科学 | 37篇 |
基础医学 | 176篇 |
口腔科学 | 26篇 |
临床医学 | 77篇 |
内科学 | 193篇 |
皮肤病学 | 27篇 |
神经病学 | 21篇 |
特种医学 | 132篇 |
外科学 | 141篇 |
综合类 | 138篇 |
预防医学 | 79篇 |
眼科学 | 4篇 |
药学 | 54篇 |
中国医学 | 39篇 |
肿瘤学 | 381篇 |
出版年
2023年 | 10篇 |
2022年 | 16篇 |
2021年 | 33篇 |
2020年 | 24篇 |
2019年 | 18篇 |
2018年 | 27篇 |
2017年 | 23篇 |
2016年 | 24篇 |
2015年 | 55篇 |
2014年 | 66篇 |
2013年 | 57篇 |
2012年 | 87篇 |
2011年 | 70篇 |
2010年 | 86篇 |
2009年 | 85篇 |
2008年 | 50篇 |
2007年 | 51篇 |
2006年 | 75篇 |
2005年 | 56篇 |
2004年 | 42篇 |
2003年 | 44篇 |
2002年 | 35篇 |
2001年 | 34篇 |
2000年 | 34篇 |
1999年 | 30篇 |
1998年 | 50篇 |
1997年 | 63篇 |
1996年 | 53篇 |
1995年 | 42篇 |
1994年 | 35篇 |
1993年 | 34篇 |
1992年 | 9篇 |
1991年 | 13篇 |
1990年 | 12篇 |
1989年 | 27篇 |
1988年 | 23篇 |
1987年 | 17篇 |
1986年 | 17篇 |
1985年 | 10篇 |
1984年 | 10篇 |
1983年 | 2篇 |
1982年 | 9篇 |
1981年 | 8篇 |
1980年 | 11篇 |
1979年 | 3篇 |
1977年 | 6篇 |
1976年 | 7篇 |
1975年 | 3篇 |
1958年 | 4篇 |
1957年 | 2篇 |
排序方式: 共有1611条查询结果,搜索用时 15 毫秒
91.
92.
93.
Ghadirian P Lubinski J Lynch H Neuhausen SL Weber B Isaacs C Baruch RG Randall S Ainsworth P Friedman E Freidman E Horsman D Tonin P Foulkes WD Tung N Sun P Narod SA 《International journal of cancer. Journal international du cancer》2004,110(3):413-416
The effect of cigarette smoking on the risk of breast cancer is controversial, although most studies show little or no effect. It has been suggested that smoking may reduce the risk of developing hereditary breast cancer. We completed a case-control study on 1,097 women with breast cancer who were BRCA1 or BRCA2 mutation carriers and 1,097 age-matched controls with a mutation in the same gene but without breast cancer. There were no statistically significant differences between the cases and controls in terms of the number of current and ex-smokers (41.2% and 40.4%, respectively) or the age at smoking commencement (18.2 years and 18.5 years, respectively). There were no statistically significant differences between cases and controls regarding beginning smoking within 5 years of menarche (OR = 1.03; 95% CI 0.83 to l.28) or before the first pregnancy (OR = 1.09; 95% CI = 0.90 to 1.33). In conclusion, contrary to our previous report, smoking does not appear to be a risk factor for breast cancer among carriers of BRCA mutations. 相似文献
94.
95.
Cleary SP Zhang W Di Nicola N Aronson M Aube J Steinman A Haddad R Redston M Gallinger S Narod SA Gryfe R 《Cancer research》2003,63(8):1769-1771
Bloom syndrome is an autosomal recessive disorder whose characteristics include an increased risk for many types of cancers. In contrast to the homozygous mutations of Bloom syndrome, heterozygous carriers of BLM mutations may be at increased risk for developing colorectal cancer. We have screened 2,333 Jewish individuals, including 497 individuals with colorectal cancer, 125 with adenomatous polyps, 767 with noncolorectal cancers and 944 controls for the truncating BLM(Ash) founder mutation. The BLM(Ash) mutation was carried by 0.80% of individuals with colorectal neoplasia, 0.87% of those with any type of cancer and 0.85% of controls. In addition to case-control data, we found no evidence to support a significant relationship between increased cancer risk and heterozygous BLM(Ash) mutations with respect to age of cancer diagnosis, tumor multiplicity or family cancer history. 相似文献
96.
Improved survival in women with BRCA-associated ovarian carcinoma 总被引:12,自引:0,他引:12
BACKGROUND: The objective of this study was to determine the clinical characteristics, treatment response, and frequency of p53 overexpression in Ashkenazi Jewish women with hereditary ovarian carcinoma. METHODS: Seventy-one Jewish women with epithelial ovarian carcinoma (EOC) were tested for the three BRCA founder mutations using single-strand conformation polymorphism analysis, heteroduplex analysis, and protein truncation testing. Clinical and histopathologic data were reviewed retrospectively. In vitro chemoresistance was analyzed in 32 patients. Mutations of p53 were studied using immunohistochemical detection of p53 overexpression. RESULTS: Thirty-four of 71 Jewish patients with EOC (48%) had germline BRCA mutations (BRCA heterozygotes), including 22 BRCA1 mutations and 12 BRCA2 mutations. BRCA heterozygotes were younger compared with Jewish patients who had EOC without mutations (sporadic carcinoma; 50 years vs. 59 years, respectively; P = 0.01). BRCA1 heterozygotes were younger compared with BRCA2 heterozygotes (48 years vs. 57 years, respectively; P = 0.01). Histopathologic tumor features were similar; however, tumors with low malignant potential were seen only in women with sporadic carcinoma. Both groups had equivalent rates of surgical cytoreduction and similar median follow-up (72 months). BRCA heterozygotes had higher response rates to primary therapy compared with patients who had sporadic disease (P = 0.01). In vitro chemoresistance predicted tumor response to platinum chemotherapy correctly in BRCA heterozygotes (P = 0.0096). BRCA heterozygotes with advance-stage disease had improved survival compared with patients who had advanced stage sporadic carcinoma (91 months vs. 54 months, respectively; P = 0.046) and had a longer disease free interval (49 months vs. 19 months, respectively; P = 0.16). p53 overexpression was common in BRCA heterozygotes (80%). CONCLUSIONS: BRCA1 heterozygotes developed EOC at a younger age compared with BRCA2 heterozygotes and women who had sporadic ovarian carcinoma. BRCA heterozygotes had a better response to platinum chemotherapy compared with women who had sporadic disease, which may have contributed to their improved prognosis. 相似文献
97.
98.
99.
100.
Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? 总被引:1,自引:0,他引:1
Goshen R Chu W Elit L Pal T Hakimi J Ackerman I Fyles A Mitchell M Narod SA 《Gynecologic oncology》2000,79(3):477-481
BACKGROUND: Uterine papillary serous carcinoma (UPSC) shares common pathologic, genetic, and clinical features with other serous cancers of müllerian origin. The most common histologic type of ovarian tumor associated with BRCA mutations is papillary serous. Because of these histologic similarities, we postulated that, in some cases, UPSC may be a manifestation of a field defect in BRCA1 carriers, which also includes ovarian carcinoma, fallopian tube carcinoma, and primary peritoneal carcinoma. METHODS: Fifty-six living patients with UPSC were contacted through their treating physicians and agreed to a family history interview and to provide a blood specimen for BRCA testing. The protein truncation test was used to detect mutations in exons 10 and 11 of BRCA1 and in exon 11 of BRCA2. The presence of four common mutations was assessed by PCR-based specific assays. RESULTS: A high proportion of patients had a past history of breast cancer (11%) or a first-degree relative with breast cancer (29%). Four patients were from families with site-specific hereditary breast cancer. However, there was no clear example of the hereditary breast-ovarian cancer syndrome, and none of the 56 patients was found to carry a BRCA1 or BRCA2 mutation. CONCLUSIONS: BRCA mutations do not appear to predispose to UPSC and this type of cancer does not appear to be a manifestation of the classical hereditary breast-ovarian cancer syndrome. The observed association between UPSC and breast cancer may be due to the presence of mutations in other cancer predisposing genes. 相似文献